---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019353"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:21:58.962966+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics forms Scientific Advisory Board to advance RedTail platform and CLD-401

## Summary
- SAB members include Drs. Mace Rothenberg (ex-Pfizer CMO), Dmitriy Zamarin (Mount Sinai), John Wrangle (MUSC), David Curiel (WashU).
- RedTail platform uses enveloped vaccinia virus overexpressing CD55 for systemic delivery of genetic medicines to tumor sites.
- Lead candidate CLD-401, in IND-enabling studies, targets NSCLC, head & neck, and other cancers with high unmet need.
- CLD-401 is designed to home to metastases, replicate only in tumor cells, and express IL-15 superagonist.
- SAB will guide efficient development of CLD-401 into the clinic and advance RedTail platform utility.

## SEC filing metadata
- accession: 0001493152-25-019353
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315225019353/0001493152-25-019353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315225019353/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019353
- JSON: https://secwatch.observer/filing/0001493152-25-019353.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.